Long-term Survival After Surgery Compared With Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer

Yang, Chi‐Fu Jeffrey; Chan, David Y.; Shah, Shivani A.; Yerokun, Babatunde A.; Wang, Xiaofei F.; D’Amico, Thomas A.; Berry, Mark F.; Harpole, David H.

doi:10.1097/sla.0000000000002287

Cited by 78 publications

(79 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Quoix et al (17) study published in 1990, they found a pulmonary nodule in 25 of 408 SCLC patients during a 5-year period. Additionally, a total of 2301 patients with T1 and T2 N0 small cell lung cancer in the national cancer database between the years of 2003-2011 were reviewed in Yang et al (18) latest article published in 2017. Surgical treatment and chemotherapy were used together in 681 of these patients who had a solitary pulmonary nodule.…”

Section: Treatment Optionsmentioning

confidence: 99%

Surgical Treatment in Small Cell Lung Cancer: Delayed Evaluation?

Işık¹,

Ulusan²,

Şanlı³

2018

Eur J Ther

View full text Add to dashboard Cite

Lung cancers are the most common solid organ cancers and are responsible for a major part of cancer deaths. They account for 1/3 or 1/4 of all deaths from cancer. Small cell lung cancers (SCLC) are known for having very poor outcomes in survival analyses, despite multiple treatment applications. Even though the traditional literature claims that treatment of this disease is essentially medical, surgical experiences do not confirm such claim. In this study, we examined whether small cell lung cancer is a non-surgical disease as it is believed to be. The medical literature in the thoracic and cardiovascular surgery and oncology network was reviewed, and studies, cases, and meta-analysis articles that provided small cell lung cancer treatment outcomes were examined. A discussion was made by also analyzing the survival data in the light of the available guidelines. It is seen that treatment of small cell lung cancer is not mainly medical and that the surgical option can be administered similarly to non-small cell lung cancer (NSCLC). Unfortunately, even the targeted treatment options do not provide recovery at a satisfactory level in the current state of cancer treatment. Surgery option keeps it validity as the most important weapon against all stages and cell types in lung cancer.

show abstract

Section: Treatment Optionsmentioning

confidence: 99%

Surgical Treatment in Small Cell Lung Cancer: Delayed Evaluation?

Işık¹,

Ulusan²,

Şanlı³

2018

Eur J Ther

View full text Add to dashboard Cite

show abstract

“…Two large cohort study suggests an increased role of surgery in multimodality therapy for early-stage SCLC. 3,4 These results might indicate that surgery could be a treatment option even in locally-advanced disease after appropriate patient selection.…”

Section: Introductionmentioning

confidence: 98%

“…10,11 However, in SCLC, NLR and PLR studies were reported exclusively from East Asia, and data have not yet been published on Caucasian or resected stage populations. [1][2][3][4][5][6] All in all, although surgical treatment of SCLC is challenging, in this study, we aim to identify biomarkers that help in patient selection that potentially benefit from lung resection.…”

Section: Introductionmentioning

confidence: 99%

Peer Review #1 of "Neutrophil–lymphocyte ratio is prognostic in early stage resected small-cell lung cancer (v0.2)"

2019

View full text Add to dashboard Cite

Background For selected early-stage small cell lung cancer (SCLC), curative intent surgery is often performed. Previous studies, predominantly from East Asia, reported that high neutrophil to lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) correlate with poor prognosis in several types of tumors including SCLC. Our aim was to investigate the prognostic value of NLR and PLR in Caucasian patients with resected SCLC, as potential tool to select patients for multimodal treatment including surgery. Methods Consecutive patients evaluated at three centers between 2000 and 2013 with histologically confirmed and surgically resected SCLC were retrospectively analyzed. NLR and PLR at diagnosis was used to categorize patients into "high" and "low" groups based on ROC analysis. Univariate and multivariate analyses were used to evaluate the impact of clinical and pathological characteristics on outcome. Results There were a total of 189 patients with a median age of 58 years, and the majority had stage I or II disease. We found a significant correlation between NLR and tumor stage (p=0.007) and age (p=0.038). Low NLR (LNLR) was associated with significantly longer overall survival (OS), while PLR had no prognostic impact. There were significant associations between NLR and PLR but not with gender, vascular involvement, tumor necrosis, peritumoral inflammation, or tumor grade. Conclusion Pre-operative LNLR may be a favorable prognostic factor in stage I-II SCLCs. PLR is not prognostic in this population. LNLR is easy to assess and can be integrated into routine clinical practice. Further prospective studies are needed to confirm these observations.

show abstract

“…While there are no recent randomized controlled trials (RCTs) of acceptable quality evaluating the use of surgery for early stage SCLC (7), large database studies have suggested that there may be a survival benefit to surgical resection (8)(9)(10)(11)(12). These findings have supported the current inclusion of surgical therapy in the National Cancer Care Network (NCCN) guidelines for early stage SCLC.…”

mentioning

confidence: 97%